However, by observing these indicators of TMB and IPS in breast cancer immunotherapy, we can also find that the expression of PAIP2 is negatively correlated with TMB and IPS in cancer immunotherapy, suggesting that PAIP2 has potential value in predicting the therapeutic effect of breast cancer immunotherapy (Charoentong et al., 2017; Samstein et al., 2019). The gene discussed is PAIP2; the disease is breast cancer.